Treatment of Hereditary C1 Inhibitor Deficiency in Children Under 12 Years

Children under 12 with hereditary C1 inhibitor deficiency who experience acute attacks require an age-appropriate management strategy. The approach differs from adult protocols in meaningful ways, reflecting the particular physiological vulnerabilities of this age group.

Clinical scenario

This protocol applies to patients with hereditary C1 inhibitor deficiency who are under 12 years of age. The pediatric age group presents specific considerations — particularly around abdominal attacks — that must be accounted for in any management plan.

Treatment approach — partial overview

Acute attacks in this age group are addressed with specific approved on-demand therapies. Abdominal attacks may warrant additional supportive measures beyond standard attack treatment.

The complete regimen — full agent selection, sequencing, and clinical decision criteria — is available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/all.15214

We recommend C1 inhibitor or icatibant be used for the treatment of attacks in children under the age of 12.
C1-INH and icatibant are the only approved on-demand treatments for children with HAE-1/2.
For abdominal attacks, parenteral fluid replacement may be required as children are more susceptible to hypovolemia and dehydration, and extravasation into the peritoneal cavity and the intestinal lumen can be substantial.

View source ↗